Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

25 May 2016 - 27 May 2016
06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016

Fine-Tuning Liver Glucose Metabolism

By Biotechdaily staff writers
Posted on 30 Jun 2006
Print article
Researchers have traced the biochemical mechanism responsible for modulating the uptake, release, and synthesis of glucose by the liver.

Previous findings had shown that hormonal and nutrient regulation of glucose synthesis in the liver was controlled by modulation of the transcriptional coactivator protein PGC-1-alpha. In the current study, investigators at Johns Hopkins University (Baltimore, MD, USA) learned that PGC-1-alpha resides in a multi-protein complex containing the acetyltransferase GCN5. Fine-tuning of glucose metabolism depends on inactivation of PGC-1-alpha by this enzyme and its subsequent sequestering away from the genes it was normally meant to activate.

This mechanism was demonstrated experimentally by using an adenovirus vector to implant the gene for GCN5 into the livers of a group of starved mice. Normally such animals are actively releasing glucose into the blood, but results published in the June 2006 issue of Cell Metabolism showed that glucose release in these genetically engineered animals was significantly reduced.

"These results show that changing GCN5 is sufficient to control the sugar balance in mice,” explained senior author Dr. Pere Puigserver, assistant professor of cell biology at Johns Hopkins University. "Therefore, GCN5 has the potential to be a target for therapeutic drug design in the future. Understanding the ways that energy production and use are controlled is crucial to developing new drugs and therapies.”



Related Links:
Johns Hopkins University

Print article

Channels

Genomics/Proteomics

view channel
Image: Follicular helper T-cells (TFH cells, shown in blue) play a crucial role in the maturation of antibody-producing B-cells (shown in green). Activated B-cells give rise germinal centers (shown in red), where mature B-cells proliferate and produce highly specific antibodies against pathogens. Top left: normal germinal center in a mouse tonsil. All others: Germinal centers fail to form when the interaction between ICOS and TBK1 is interrupted (Photo courtesy of Dr. Kok-Fai Kong, La Jolla Institute for Allergy and Immunology).

Molecular Pathway Controlling High-affinity Antibody Production Identified

A molecular pathway has been identified that controls formation of follicular helper T-cells (TFH cells) germinal centers and production of high-affinity antibodies through interaction with the inducible... Read more

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.